Biomarkers · Renal & Purine

Alpha-1-Microglobulin

Lower values go with lower risk of death. No risk curve catalogued yet.

Published risk of death1.29×per doubling of urine alpha-1-microglobulin concentration (95% CI 1.10–1.51) · Health, Aging, and Body Composition (Health ABC) Study random subcohort, mean age 74 years, USA (urine A1M)

What studies found when this marker was changed

They describe what happened in those study groups, not a recommendation. See all catalogued interventions.

Measured changes in Alpha-1-Microglobulin, study by study

2 effects with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.

Each row is one study: what was changed, the effect it reported on this marker, and the source.
Type	Intervention	Reported effect	Evidence	Source
clinical	Intensive (<120 mm Hg) vs standard systolic blood pressure target in SPRINT participants with chronic kidney disease (urine A1M/creatinine)	Urine A1M/creatinine 24% lower (95% CI 10% to 36%) with intensive vs standard BP control at year 1; n=978	RCT	Malhotra R, et al. Am J Kidney Dis. 2019;73(1):21-30.

Things that worsen it

Each row is one study: what was changed, the effect it reported on this marker, and the source.
Type	Condition or exposure	Reported effect	Evidence	Source
pharmacologic	Empagliflozin 10 mg once daily vs placebo in adults with chronic kidney disease at risk of progression (EMPA-KIDNEY urine biomarker study)	Increases urinary alpha-1-microglobulin (indexed to creatinine) by 29% (95% CI 25-34%) averaged across 2 and 18 months	RCT	Malijan GB, et al. American journal of kidney diseases : the official journal…

What else moves this marker

They describe those study groups, not an individual, and an association is not a cause.

Diseases and conditions

Each row is one study: what it compared and the change it reported in this marker.
What	Effect on the marker	Comparison · population	Source
↑ Acute kidney allograft rejection · Urinary A1MG, biopsy-proven acute rejection vs stable graft function, postoperative day 3-10	+7.07 mg/L	Rejection 29.13 vs stable 22.06 ug/mL (difference by subtraction; ug/mL = mg/L) · Kidney transplant recipients (58 rejection, 58 stable)	case control · PMID 24549629

Sources

Jotwani et al. Urinary Biomarkers of Kidney Tubular Damage and Risk of Cardiovascular Disease and Mortality in Elders. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2018;72:205-213.